Humoral rejection is refractory to conventional high-dose corticosteroid pulse therapy and invariably requires the addition of depleting antibodies, either polyclonal antilymphocyte agents or OKT3.

There has been a great deal of recent work that has used the combination of plasmapheresis and intravenous immunoglobulin (IVIG) to treat humoral rejection. It seems to be an important advance.

A research study at the University of Chicago has found that in pregnancy, while the T cell response to a fetus becomes tolerant to allow for successful pregnancy, the part of the immune system that ...

Amid the debate over which combination of immunosuppressive agents works best in helping patients fight off rejection of their new heart after transplant surgery, a new study led by researchers at the ...

Antibody-mediated rejection is a leading cause of kidney-transplant failure. The targeting of CD38 to inhibit graft injury caused by alloantibodies and natural killer (NK) cells may be a therapeutic ...

NK-CHAT may help detect antibody-mediated rejection earlier after kidney transplantation by measuring functional NK cell ...

A research study has found that in pregnancy, while the T cell response to a fetus becomes tolerant to allow for successful pregnancy, the part of the immune system that produces antibodies (known as ...

To investigate the role of DSAs in allo-SCT, we first examined a case of cord blood allograft rejection. DSA and donor HLA-specific cytotoxic T lymphocyte (CTL) recognizing the same alloantigen of the ...

IN recent months it has become increasingly evident that humoral antibodies as well as cellular immune mechanisms sometimes play an active part in the rejection of human kidney transplants. Several ...